Project ID：DT-202500410-037
Product Brief Summary
- Product Name: First-in-class Phase I Dual-target Oral Molecular Glue for Hematologic Malignancies with Broad-spectrum Activity and Better Safety Profile
- Target: GSPT1 and IKZF1/3
- Modality: Molecular Glue
- Therapeutic Area: Hematologic Malignancies
- Current Stage: Phase I
- Rights Available: China/Global Right
- Collaboration Mode: License out / co-development
More highlights
- Degradation of dual targets GSPT1 and IKZF1/3 synergistically treats AML, MM, and NHL.
- Same broad spectrum activity yet more active than CC – 90009
- 25 times more effective than CC-90009
- 25 times higher than the safety window of CC-90009
- Only drug does not reduce PLT and HGB in the world
- T1/2 is 8.5 times that of CC-90009
Contact us:
For any questions, please contact DrugTimes BD Team at BD@drugtimes.cn, please include Project ID in the subject. Many thanks!
发布者：qi.yang，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 